Home › ALKEM › Filing
🔔 Get instant alerts when ALKEM files quarterly results on BSE Start free trial →

Analysts/Institutional Investor Meet/Con. Call Updates

Filed: 18 Nov 2026, 12:38 IST Exchange: NSE Category: Financial Results — Earnings Call Transcript
AI summary - Q2 FY27 revenue INR 4,520 Cr +13.8% y-y; EBITDA INR 1,025 Cr +11.3%, margin 22.5% - India formulations growth in line with market; chronic segment +22.4%, outperforming IPM by 640 bps - U.S. business volume +10%, price erosion 16%, new launches limited by OAI status - Non-U.S. markets strong with 58% growth led by LATAM, Australia, Europe; mid-teens growth expected - Enzene biotech and MedTech drag margins by ~100 bps; break-even expected in 18 months - Capex planned: INR 300-350 Cr for Enzene, INR 400 Cr for MedTech over 3-4 years - Daman facility remediation ongoing; 8 product launches delayed impacting U.S. growth - FY27 EBITDA margin guidance maintained at 20-21%; pharma core margin ~26% in Q2 - Chronic segment focus with leadership in multivitamins and semaglutide volumes - Occlutech integrated from July 16; gross margin ~80%, U.S. ramp-up expected in 2028
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 ALKEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add ALKEM to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Alkem Laboratories Limited

Important. The summary above is generated automatically from Alkem Laboratories Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.